FDA Approves Igalmi for Agitation | Psychiatric News
WEBMay 5, 2022 · The Food and Drug Administration (FDA) in April approved a sublingual formulation of dexmedetomidine under the brand name of Igalmi for the treatment of agitation associated with schizophrenia or bipolar I or II disorder. Dexmedetomidine was previously approved in intravenous form for anesthesia.
BioXcel Therapeutics Announces Clinical ... - Markets Insider
WEB1 day ago · Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI™ (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film ...
NAN Alert: Manufacturer's Product Labeled as Acetaminophen …
WEBJul 11, 2024 · Hikma's dexmedeTOMIDine premixed intravenous (IV) bags may be packaged within an overwrap labeled as acetaminophen, according to a new warning from the National Alert Network (NAN).
Warnings of new deadly chemical in street drug supply : NPR
WEBMay 29, 2024 · Public health officials say Mexican cartels and drug gangs inside the U.S. are mixing a dangerous chemical sedative called medetomidine into fentanyl and other drugs sold on the street. The...
Dexmedetomidine or Propofol for Sedation in Mechanically …
WEBFeb 2, 2021 · Guidelines currently recommend targeting light sedation with dexmedetomidine or propofol for adults receiving mechanical ventilation. Differences exist between these sedatives in arousability,...
Dexmedetomidine for agitation in dementia: Current data and …
WEB1 day ago · Dexmedetomidine has shown benefit for hospital delirium and for agitation in schizophrenia and bipolar disorder. However, there are no completed studies published on dexmedetomidine for agitation in dementia. Controlled studies with larger sample sizes are needed to assess the efficacy, safety, and the best route of administration for this drug ...
Dexmedetomidine Transdermal Patch Fast Tracked for Postop …
WEBJun 21, 2023 · Teikoku Pharma granted FDA Fast Track designation for TPU-006, a novel 4-day dexmedetomidine transdermal system for postoperative pain management. News release. June 21, 2023.
FDA Approves Dexmedetomidine for Agitation From Bipolar …
WEBApr 7, 2022 · The FDA has approved dexmedetomidine (Igalmi, BioXcel Therapeutics) sublingual film for the treatment of adults with agitation associated with bipolar disorders 1 and 2 and schizophrenia. Dexmedetomidine can be self-administered under the supervision of a health care provider.
Sublingual Dexmedetomidine Promising for Acute Agitation …
WEBJul 20, 2020 · Dexmedetomidine is currently available as a solution for intravenous infusion for use in clinical anesthesia and sedation in an intensive care setting. BXCL501 is an investigational proprietary...
Early Sedation with Dexmedetomidine in Critically Ill Patients
WEBMay 19, 2019 · Dexmedetomidine produces sedation while maintaining a degree of arousability and may reduce the duration of mechanical ventilation and delirium among patients in the intensive care unit (ICU)....